Treatment Information

Back

Melanoma treatment details. Biologic therapy.

National Cancer Center Hospital, Tokyo, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:3City/State/Province:Tokyo
Treatments:Biologic therapyHospital:National Cancer Center Hospital
Drugs:Journal:Link
Date:Jul 2015

Description:

Patients:
This phase 1/2 study involved 11 melanoma patients who had the BRAFV600 mutation. The median patient age was 49 years and 3 were male.

Treatment:
Patients received biologic therapy with vemurafenib, a kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe toxicities were of grade 3 and included rash and liver toxicity. Grade 2 fever, headache, and fatigue were also reported.

Results:
The median overall survival was 13.9 months.

Support:
This study was supported by Chugai Pharmaceutical.

Correspondence: Dr. Naoya Yamazaki; email: [email protected]



Back